

April 20, 2016

BSE Limited
Corporate Service Department
1st Floor, New Trading Ring
Rotunda Building, P.J. Tower
Dalal Street, Fort
Mumbai - 400 001

The National Stock Exchange of India Ltd.
Exchange Plaza
Bandra Kurla Complex
Bandra (E)
Mumbai – 400 051

Dear Sirs,

Sub.: Intimation of Schedule of Investor/Analyst meetings on April 22 and 25, 2016

Pursuant to the provisions of Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, we enclose the details of investor/analyst meetings scheduled on April 22 and 25, 2016.

The schedule may undergo change due to exigencies on the part of Investors/Analysts/ Company.

We also enclose the presentation to be used during the meetings.

This is for your kind information and record.

Thanking you,

Yours faithfully,
For Jubilant Life Sciences Limited



Rajiv Shah
Company Secretary

Encl.: as above

A Jubilant Bhartia Company

OUR VALUES



Jubilant Life Sciences Limited
1-A, Sector 16-A,
Noida-201 301, UP, India
Tel: +91 120 4361000
Fax: +91 120 4234895-96
www.jubl.com

Regd Office:
Bhartiagram, Gajraula
Distt. Amroha - 244 223,
UP, India
CIN : L24116UP1978PLC004624

Investor/Analyst meetings scheduled on 22nd and 25th April, 2016

S. No.	Meeting Date	Type of Meeting	Name of Fund/Firm	Location
1	22 nd April, 2016	Group	1. BlackRock, Inc. 2. Fidelity Management & Research 3. Iridian 4. JP Morgan & Co. 5. Putnam 6. TIAA – Cref 7. Wellington Management 8. Visium Asset Management 9. ABR Healthco 10. Capital Invest Trust, Taiwan 11. Yuanta Securities Investment Trust Company, Taiwan 12. IDFC Securities Limited	National Capital Region
2.	25 th April, 2016	One-On-One	1. Emkay Global Financial Services 2. Sharekhan Ltd. 3. UBS Securities 4. Systematix Shares & Stocks (I) Ltd.	Mumbai



Jubilant Life Sciences

April 2016

Disclaimer

Important Disclaimer

This presentation (the "Presentation", or the "document") has been prepared by Jubilant Life Sciences Limited (the "Company") for the recipient for the purpose of providing information on the Company. The contents of this Presentation are confidential and strictly for use by the recipient only. The Presentation shall not, in whole or in part, be disclosed without prior written consent of the Company. This Presentation must not be copied, reproduced, distributed, or otherwise disclosed or passed on to others, in whole or in part, by any means, in any form under any circumstances whatsoever at any time hereafter. The recipient agrees to keep confidential any information contained herein and any other written or oral information otherwise made available in connection with the Company. In furnishing this document, neither the Company, nor its associates and affiliates, nor any of their respective officers, directors, advisors, undertake any obligation to provide to the recipient (a) access to any additional information or to update this document, or (b) to correct any inaccuracies therein which may or may not become apparent.

This Presentation may contain statements about events and expectations that may be "forward-looking", including statements relating to future status, events, prospects or circumstances, including but not limited to statements about plans and objectives, outlook, the progress and results of research and development, potential product characteristics and uses, product sales potential and target dates for product launch are forward-looking statements based on estimates and the anticipated effects of future events on current and developing circumstances. Such statements are subject to numerous risks and uncertainties and are not necessarily predictive of future results. Actual results may differ materially from these forward-looking statements due to number of risks and uncertainties, including future changes or developments in the Company's business, its competitive environment, its ability to implement its strategies and initiatives, respond to industry changes and the political, economic, regulatory and social conditions in India. The Company may, from time to time, make additional written and oral forward looking statements, including statements contained in the company's filings with the regulatory bodies and our reports to shareholders. The Company assumes no obligation to update forward-looking statements to reflect actual results, changed assumptions or other factors.

This Presentation does not constitute a prospectus, offering circular or offering memorandum or an offer invitation or a solicitation of any offer to purchase or sell, any securities of the Company, and should not be considered or construed in any manner whatsoever as a recommendation that any person should subscribe for or purchase any of Company's securities. None of the projections, expectations, estimates or prospects in this Presentation should be construed as a forecast implying any indicative assurance or guarantee of future performance, nor that the assumptions on which such future projections, expectations, estimates, or prospects have been prepared are complete or comprehensive.

This Presentation utilises information which has not been independently verified (including by opinion, anecdote and speculation) and which has been sourced from a variety of public sources and third parties. Neither the Company, nor its associates and affiliates, nor any of their respective officers, directors, advisors, makes any representation or warranty (expressly or impliedly) as to the accuracy, adequacy or completeness of this document or its contents or of any other oral or written information furnished or made available. The Company disclaim to the extent possible by law, all responsibility in relation to this Presentation.

This Presentation, is not a recommendation to invest, is not an investment advice, and, is prepared to provide background information for investors in relation to the Company. This Presentation does not purport to contain all information investors may require to evaluate an investment in the Company. In preparing the Presentation, the Company have not taken into account the particular investment objectives, financial situation or particular needs of investors. Before making an investment decision, an investor should independently consider whether an investment in the Company is appropriate in light of its particular investment needs, objectives and financial circumstances. An investor should conduct its own independent investigations, due diligence and analysis of the potential benefits and risks of any investment in the Company. An investor should seek professional advice, including tax advice before making an investment decision.

The distribution of this Presentation in or from certain jurisdictions may be restricted or prohibited by law. Recipients are required to inform themselves of, and comply with, all restrictions or prohibitions in such jurisdictions. Neither the Company nor any other person shall have any liability to any person in relation to the distribution or possession of this document or copies thereof in or from any jurisdiction where the distribution of such a document is prohibited or requires special authorisation or any regulatory consent or approval. By accepting this document the recipient has agreed, upon request, to return promptly all material received from the Company without retaining any copies.

By accepting this Presentation, the recipient agrees that this Presentation is strictly confidential and shall not be copied, published, distributed or transmitted to any person, in whole or in part, by any means, in any form under any circumstances whatsoever and that the recipient has further agreed, upon request, to return promptly all material received from the Company without retaining any copies. The recipient further represents and warrants that it is lawfully able to receive this Presentation under the laws of the jurisdiction in which it is located and / or any other applicable laws, and that it will not reproduce, publish, disclose, redistribute or transmit this Presentation.

NOTES

1. The numbers for the quarter have been reclassified and regrouped wherever necessary
2. Closing Exchange Rate for USD 1 at Rs. 63.03 as on December 31 '14 & Rs. 66.16 as on December 31 '15
3. The Exchange fluctuation on long term forex loans in Indian books have been amortized over the tenure of the loan period as recommended under Indian Accounting Standards

Jubilant Life Sciences At a Glance

- ▶ **Global integrated pharma and life sciences solutions provider** with a track record of 37 years
- ▶ **'Caters to 19 of top 20 pharmaceutical companies** and 7 of top 10 leading global agrochemical companies
- ▶ Strategic presence in **Injectables with USFDA approved Manufacturing facilities** in North America
- ▶ **Strong positions** in products across niche businesses such as **Radiopharmaceuticals/Allergy Therapy Products**
- ▶ **Expertise in Chemistry** and manufacturing spans across over three decades of experience
- ▶ Strong international presence with 71% of sales coming from over 100 countries, about **50% of asset base in North America** and **42%⁽¹⁾ of total revenue contribution from North America**
- ▶ **4 USFDA approved manufacturing facilities** in North America⁽²⁾ and 2 USFDA approved manufacturing facilities in India
- ▶ **5 state-of-the-art** Life Sciences Ingredients manufacturing facilities in India
- ▶ Employs over 6,000 people globally, **including about 1,300 in North America** and **about 950 dedicated to R&D**



Note:

EBITDA includes other income of INR299m, INR191m, INR425m, INR111m and INR366m for FY13, FY14, FY15, 9M FY16 and 9M FY15 respectively
EBITDA is pre-corporate expenses of INR 602m, INR668m, INR350m, INR225m and INR318m for FY13, FY14, FY15, 9M FY15 and 9M FY16 respectively
EBITDA margin is post-corporate expenses

Fiscal Year End March, 9M FY15 represents 9 months period ended Dec 2014; 9M FY16 represents 9 months period ended Dec 2015

(1) For the period 9M FY16

(2) Includes Solid Dosage Formulations facility in Maryland, Radiopharmaceuticals facility in Montreal and CMO facilities in Montreal and Spokane



Jubilant Life Sciences Overview

Pharmaceuticals

Generics

- ✓ Active Pharmaceutical Ingredients
- ✓ Solid Dosage Formulations
- ✓ Indian Branded Pharmaceuticals

Specialty Pharmaceuticals (Sterile Products)


- ✓ CMO of Sterile Injectables
- ✓ Radiopharmaceuticals
- ✓ Allergy Therapy Products
- ✓ Drug Discovery Solutions

Life Sciences Ingredients


Specialty Intermediates and Nutritional Products

Life Sciences Chemicals


9M FY16 Revenue Mix by Segment




9M FY16 Revenue Contribution by Region



9M FY16 EBITDA Mix by Segment




Increasing Focus Towards Specialized Pharmaceutical Solutions




Business Evolution

Revenue




EBITDA




EBITDA is pre corporate expenses
Pharma includes API, Dosage forms, Radio Pharma, Allergenic Extracts, CMO and Drug Discovery and Development Services.

Performance Back on Track With Business Related Concerns Resolved

Strong Turnaround in Jubilant Life Sciences' EBITDA...



...and Normalized Net Income⁽¹⁾



Successful Resolution of Warning Letters at Montreal and Spokane

Montreal CMO Facility

- ▶ In Feb 2013, Jubilant's manufacturing facility Jubilant HollisterStier (JHS) located at Kirkland, Quebec, Canada received a Warning Letter from the FDA
- ▶ The facility engages in contract manufacturing of injectables for large pharma companies and also for the Radiopharma business
- ▶ It was re-inspected in Sep 2013 and all issues related to the facility were successfully resolved in Feb 2014 with the warning letter closed out in Sep 2014

Spokane CMO Facility

- ▶ In Dec 2013, Jubilant's manufacturing facility JHS located at Spokane, Washington State, US received a Warning Letter from the FDA
- ▶ During H1 FY14, the contract manufacturing operations at Spokane contributed 7% to consolidated sales and 4% to consolidated EBITDA.
- ▶ The facility was re-inspected by FDA in Apr 2014 and Dec 2014
- ▶ In Jun 2015, Spokane facility was upgraded to the status of Voluntary Action Indicated (VAI) and ramp up of operations is underway
- ▶ Successful inspection of the facility by USFDA in July 2015
- ▶ Fast resolution of Warning Letters at CMO facilities within 12-15 months

Note: Fiscal Year End March, 9M FY15 represents 9 months period ended Dec 2014; 9M FY16 represents 9 months period ended Dec 2015
 (1) Normalized Net Income defined as Net Income before Exceptional Gains / Losses

Pharmaceuticals Business Segment

Pharmaceuticals			Revenue (INR m)																	
	Specialty Pharma (Sterile Products)	Generics																		
Overview	▶ Radio Pharma: North America market leadership in nuclear imaging products ▶ Contract Manufacturing (CMO): of sterile injectables for large pharmaceuticals and biotech companies ▶ Allergy Therapy Products: Focus on diagnostic allergenic extracts with 53% US Allergy market penetration ▶ Drug Discovery Solutions: Contract research services	▶ APIs: Vertically integrated operations with API manufacturing for captive consumption as well as external sales ▶ Solid Dosage Formulations: Strong pipeline of 71 ANDAs filed and 32 ANDAs pending approvals ▶ Indian Branded Pharmaceuticals: Recent foray with the launch of Cardiovascular and Diabetic division	<table><tr><th>Period</th><th>Revenue (INR m)</th></tr><tr><td>9M FY15</td><td>19,195</td></tr><tr><td>9M FY16</td><td>22,154</td></tr></table>	Period	Revenue (INR m)	9M FY15	19,195	9M FY16	22,154											
Period	Revenue (INR m)																			
9M FY15	19,195																			
9M FY16	22,154																			
9M FY16 Revenue Contribution	<table><tr><th>Segment</th><th>Contribution (%)</th></tr><tr><td>Specialty Pharma (Sterile Products)</td><td>28%</td></tr></table>	Segment	Contribution (%)	Specialty Pharma (Sterile Products)	28%	<table><tr><th>Segment</th><th>Contribution (%)</th></tr><tr><td>Generics</td><td>24%</td></tr></table>	Segment	Contribution (%)	Generics	24%	EBITDA (INR m) <table><tr><th>Period</th><th>EBITDA (INR m)</th><th>EBITDA Margin (%)</th></tr><tr><td>9M FY15</td><td>2,446</td><td>13%</td></tr><tr><td>9M FY16</td><td>6,598</td><td>30%</td></tr></table> ● EBITDA Margin	Period	EBITDA (INR m)	EBITDA Margin (%)	9M FY15	2,446	13%	9M FY16	6,598	30%
Segment	Contribution (%)																			
Specialty Pharma (Sterile Products)	28%																			
Segment	Contribution (%)																			
Generics	24%																			
Period	EBITDA (INR m)	EBITDA Margin (%)																		
9M FY15	2,446	13%																		
9M FY16	6,598	30%																		
Key Highlights	▶ Reported YoY growth of 35% for 9M FY16 ▶ Expect to launch new differentiated products going forward ▶ Healthy order book position in the CMO business	▶ Deep relationships in Generics industry for APIs ▶ Front-end presence in US via 100% subsidiary Cadista ▶ Received 7 ANDA approvals in 9M FY16 ▶ Launched 3 products in the US in 9M FY16 ▶ North America accounted for 87% of 9M FY16 Solid Dosage Formulations revenue																		


Note:
 EBITDA includes other income.
 EBITDA is pre-corporate expenses.
 Fiscal Year End March, 9M FY15 represents 9 months period ended Dec 2014; 9M FY16 represents 6 months period ended Dec 2015

Update on Regulatory Status

Regulatory Agency	Cadista USA	RRK India	CMO Spokane USA	CMO Montreal	JDI Montreal Canada	NNJ India
 FDA (USA)	Aug 2015	Mar 2015	Jul 2015	Nov – Dec 2015	Dec 2015	Aug 2015
 Health Canada (Canada)				Sep 2015		
 Pmda (Japan)		Dec 2015				
 CDSCO (India)		Sep 2015				
 ANVISA (Brazil)					Mar 2015	
 T.C. Sağlık Bakanlığı (Turkey)			Mar 2015			
 Cofepris (Mexico)					Aug 2015	

- ▶ Sites inspected by multiple agencies
- ▶ All sites have been inspected by FDA in the last 1 year
- ▶ Fast resolution of Warning Letters at CMO facilities within 12-15 months
- ▶ Use the experience from multiple Agency inspections to enhance compliance status of all sites
- ▶ World class quality control practices
 - Global quality control function reporting to the Corporate Board

Life Sciences Ingredients Business Segment



Note:
 EBITDA includes other income.
 EBITDA is pre-corporate expenses.
 Fiscal Year End March, 9M FY15 represents 9 months period ended Dec 2014; 9M FY16 represents 9 months period ended Dec 2015.

Key Growth Drivers – Pharmaceuticals

Pharmaceuticals	Generics	▶ Portfolio of 71 ANDAs filed with 27 pending approvals ■ Received 7 ANDA approvals in 9MFY16 – launch of approved ANDAs to drive near term growth ▶ Geographic expansion across Europe, Japan and Emerging Markets – portfolio of 664 filings and 461 approvals ex US ▶ Deep relationships with customers ▶ 79 US DMFs filed with 33 DMFs reviewed/commercialized and 46 pending commercialization ▶ Expected filings of 8-10 products annually, including specialized segments like injectables and ophthalmics
	Specialty Pharmaceuticals (Sterile Products)	▶ New launches including differentiated products such as Ruby-fill ▶ Strong order book in CMO business – expect good ramp up of operations and higher capacity utilization in the coming quarters ▶ Target deeper penetration in North America and accelerating growth to become a leading Allergy Therapy products Company in the US ▶ New targets, research opportunities and more collaborative programs in discovery services ▶ Strategic positioning in sterile injectables with limited competition ▶ Expected shortage of quality manufacturing sites for injectables in North America given increased compliance and regulatory focus

Key Growth Drivers – Life Sciences Ingredients

Life Sciences Ingredients

Specialty Intermediates and Nutritional Products

- ▶ Conversion of existing product specific plants to multi-purpose plants to meet enhanced customer demand requirements
- ▶ New Product launches in Specialty Intermediate plants
- ▶ Growth in Nutritional Products business driven by higher volume and improved pricing mix
- ▶ Increased uptick of Life Sciences intermediates for Pharma related applications
- ▶ Increased focus on new, non-traditional geographies for Pyridine
- ▶ Increased demand for higher value-added products in Fine Ingredients and Nutritional Products

Life Sciences Chemicals

- ▶ Higher capacity utilization to aid growth for Acetic Anhydride
- ▶ Expanding geographic reach into Key Markets such as US and Europe
- ▶ Cost advantages:
 - Efficient process
 - Volume advantage in procurement
 - Multimodal transportation and reverse logistics to optimize costs



Key Investment Highlights

What Makes Jubilant a Unique Investment Case?




1 Global Competitive Edge Due to Low Cost and Vertical Integration


Vertical integration across the value chain enables cost competitive advantage resulting in higher margins

Pharmaceuticals


- ▶ Presence across the spectrum offering products/services and delivering innovative solutions for customers
- ▶ APIs from the manufacturing facilities are used for dosage formulations under generic business



- ▶ Majority of commercial solid dosage formulations are based on in-house APIs
- ▶ Specialty Pharmaceuticals (Sterile Products)



Life Sciences Ingredients




2 Leadership Position in Key Products...

Pharmaceuticals	
Generics	▶ Global leadership positions in certain key API products in CVS (Valsartan, Irbesartan) and CNS (Oxcarbazepine, Carbamazepine, Tramadol, Donepezil) ▶ US leadership positions in certain Solid Dosage Formulations products in CVS (Terazosin), CNS (Prochlorperazine) and Methylprednisolone
Specialty Pharma	▶ Ranked in top 5 Contract Manufacturers in North America for sterile injectables ▶ Leader in Radiopharmaceutical products such as MAA, DTPA and I-131 ▶ Leading supplier in North America for Allergy Therapy Products
Life Sciences Ingredients	
Speciality Intermediates and Nutritional Products	▶ Global leadership position in Pyridines & 14 Pyridine derivatives ▶ Second largest producer globally in Vitamin B3
Life Sciences Chemicals	▶ Globally #4 in Acetic Anhydride (Merchant Sales) ▶ Globally #7 in Ethyl Acetate

2 ...With Strong Position in Radiopharma & Allergy Therapy Products Business

Radiopharma

- ▶ Wide array of therapeutic and diagnostic products, with market leadership and limited competition across key products in North America
- ▶ Demonstrated strong growth in Radiopharmaceuticals business (Revenue CAGR FY13-FY15 of 58%)
 - Future growth to be driven by a strong product pipeline and geographic expansion across Emerging markets
 - Ruby-fill, an infuser device used for heart imaging, currently under active FDA review, is expected to be launched in FY17



Allergy Therapy Products

- ▶ Strong market position in Allergy Therapy Products in North America
 - Among top 3 in the US for allergy immunotherapy with dominant market penetration
- ▶ US Market leader for manufacture of Stinging Insect Venom Immunotherapy Products

3 De-risked Business Model With Diverse Sources of Revenue


De-risked business model

- ▶ Presence in niche Specialty businesses that have high barriers to entry
- ▶ Forward integration in Pyridine related derivatives to ensure higher utilization and profitability
- ▶ Diverse end-use industry segmentation in Life Sciences Ingredients with focus on Pharmaceutical and Agrochemical industries


No Concentration Risk

- ▶ **Business:** Specialty Intermediates and Nutritional Products is the largest segment and accounts for 29% of FY15 Revenue
- ▶ **Customers:** Top 10 customers account for 22% of FY15 Revenue
- ▶ **Products:** Top 10 products account for 53% of FY15 Revenue
- ▶ **Geography:** 71% of FY15 Revenue from international markets with products & services reaching over 100 countries


FY15 Revenue Mix by Segment




FY15 Revenue Contribution of Top 10 Customers



FY15 Revenue Contribution of Top 10 Products




FY15 Revenue Contribution by Region




4 Strong Pipeline of Products With Deep R&D Capabilities

- Strong R&D capabilities demonstrated by complex and niche product filings in formulations and API segments
- Strong R&D support with a dedicated workforce of 935 scientists
- Cumulative R&D spend of USD 79m over FY13 to FY15
- New products have contributed to 11% of revenues during last 5 years


Ongoing Investments in R&D (USD m)




DMF Filings



ANDA Filings



ANDA Approvals



Dosage Formulation Filings

Region	Filings	Approvals	Pending Approval
USA	71	44	27
Canada	21	18	3
EU	46	46	0
Japan	1	0	1
Australia	3	3	0
ROW	593	394	199
Total	735	505	230

71 ANDAs filed
44 ANDAs approved
27 ANDAs pending approvals


79 US DMFs filed
33 DMFs Reviewed

38 commercial APIs, including
24 in North America, 23 in
Europe and 28 in ROW

51 commercial Solid Dosage
Formulations products,
including 31 in North America,
29 in Europe and 27 in ROW

Note: As of 31 Dec 2015

5 High-Quality, World-Class, Low Cost Manufacturing Footprint



4 USFDA approved manufacturing facilities in North America and 2 USFDA approved manufacturing facilities in India
 5 state-of-the-art Life Sciences Ingredients manufacturing facilities in India

6 Experienced Management Team



Shyam S Bhartia
Chairman
36 industry years in pharma, specialty chemicals, foods, oil and gas, aerospace and IT



Hari S Bhartia
Co-Chairman & Managing Director
31 industry years in pharma, specialty chemicals, foods, oil and gas, aerospace and IT



R Sankaraiah
Executive Director – Finance
30 years of Industry Experience



Shyamsundar Bang
Executive Director -
Manufacturing & Supply Chain
41 years of Industry Experience



Dr. Ashutosh Agarwal
Chief Scientific Officer
33 years of Industry Experience

Pharmaceuticals



G. P. Singh, CEO - Jubilant Pharma
22 years of Industry Experience

Life Sciences Ingredients



Pramod Yadav, Co-CEO – Life Sciences Ingredients
27 years of Industry Experience



Rajesh Srivastava, Co-CEO – Life Sciences Ingredients
27 years of Industry Experience

Drug Discovery Solutions



Steven Hutchins, President - Drug Discovery Solutions
26 years of Industry Experience


Businesses

- ✓ API
- ✓ Solid Dosage Formulations
- ✓ Radiopharmaceuticals
- ✓ CMO of Sterile Injectables
- ✓ Allergy Therapy Products
- ✓ India Branded Pharmaceuticals

- ✓ Advanced Intermediates
- ✓ Nutritional Products
- ✓ Animal Nutrition
- ✓ Ethanol

- ✓ Fine Ingredients
- ✓ Crop Science Ingredients
- ✓ Life Science Chemicals
- ✓ External Manufacturing

Shareholding Structure⁽¹⁾



(1) As of 29 Jan, 2016.


Corporate Functions

- ✓ Finance
- ✓ Operations
- ✓ Quality
- ✓ IT
- ✓ HR
- ✓ Regulatory


- ✓ Finance
- ✓ Operations
- ✓ Quality
- ✓ IT
- ✓ HR
- ✓ EHS

7 Strong Financial Track Record

Consolidated Revenue (INR m)




Consolidated EBITDA (INR m) and Margin (%)



Recent Turnaround in Business

- Warning Letters issued by the USFDA at both the Spokane and Montreal facilities have now been resolved.
- Witnessed strong performance with significant margin improvement in Radiopharma business and price increase in Niacinamide

Consolidated EBITDA (INR m)




Note:
Fiscal Year End March, 9M FY15 represents 9 months period ended Dec 2014; 9M FY16 represents 9 months period ended Dec 2015



Financial Overview

Financial Overview



Note:

(1) Includes product development expenditure.

EBITDA includes other income of INR299m, INR191m, INR425m, INR111m and INR366m for FY13, FY14, FY15, 9M FY16 and 9M FY15 respectively


EBITDA is pre-corporate expenses of INR 602m, INR668m, INR350m, INR225m and INR318m for FY13, FY14, FY15, 9M FY15 and 9M FY16 respectively

EBITDA margin is post-corporate expenses


Fiscal Year End March, 9M FY15 represents 9 months period ended Dec 2014; 9M FY16 represents 9 months period ended Dec 2015

Pharma Business: Overview


Revenue (INR m)




Revenue by Segment (9M FY16)




Revenue by Geography (9M FY16)



EBITDA (INR m)




% of Total EBITDA (9M FY16)




Note:
EBITDA is pre-corporate expenses
Fiscal Year End March, 9M FY15 represents 9 months period ended Dec 2014; 9M FY16 represents 6 months period ended Dec 2015

Life Sciences Ingredients: Overview


Revenue (INR m)




Revenue by Segment (9M FY16)




Revenue by Geography (9M FY16)



EBITDA (INR m)




% of Total EBITDA (9M FY16)



Note:
EBITDA is pre-corporate expenses
Fiscal Year End March, 9M FY15 represents 9 months period ended Dec 2014; 9M FY16 represents 6 months period ended Dec 2015


Strong Balance Sheet

Debt Overview (INR m)




Net debt reduction of INR 2,226 million in 9M FY16 on constant currency basis

Debt Maturity Profile⁽²⁾ (INR m)




Net Debt / EBITDA



Target Net Debt / EBITDA of less than 2.5x

Debt Breakdown by Currency



Reorganized debt portfolio in such a way that free cash flows would be adequate for scheduled loan repayments
Prepaid all rupee loans scheduled for repayment during next two years

Note:
Fiscal Year End March, 9M FY15 represents Dec 2014; 9M FY16 represents 9 months period ended Dec 2015

(1) Including swapped loans.
(2) As of 31st December 2015.

Historical Financials – Profit and Loss Account

INR m	FY13	FY14	FY15	9M FY16
Total Income from Operations	51,660	58,034	58,262	43,011
Material Cost	20,609	24,421	26,617	15,490
Power and Fuel Cost	3,567	3,897	3,930	2,881
Employee Cost	9,626	11,052	10,903	8,426
Other Expenses	7,299	8,588	9,920	6,639
Total Expenses	41,101	47,958	51,370	33,435
Other Income	299	190	425	111
Pharmaceuticals EBITDA	7,391	6,102	4,447	6,598
Life Sciences Ingredients EBITDA	4,069	4,832	3,220	3,407
Less: Corporate Expenses	(602)	(668)	(350)	(318)
EBITDA including other income	10,858	10,266	7,317	9,687
% Margin	21%	18%	13%	23%
Depreciation	2,538	2,812	2,880	2,200
Finance Cost	2,987	3,237	3,553	2,864
Profit after Interest but before Exceptional Items	5,333	4,217	884	4,623
Exceptional Item - Gain / (Loss)	(1,922)	(2,145)	(481)	10
Tax	1,524	696	805	1,025
Minority Interest	361	286	176	-
Reported Net Profit After Tax and Minority Interest	1,527	1,090	(578)	3,608
Normalized Net Profit after tax	3,449	3,235	(97)	3,598

Note: Fiscal Year End March, 9M FY15 represents 9 months period ended Dec 2014; 9M FY16 represents 9 months period ended Dec 2015

Historical Financials – Balance Sheet

INR m	Mar-13	Mar-14	Mar-15	Sep-15
EQUITY AND LIABILITIES				
Shareholders Funds	24,761	26,265	24,535	27,091
<i>Share Capital</i>	159	155	159	159
<i>Reserves and Surplus</i>	24,602	26,111	24,376	26,932
Minority Interest	1,115	1,579	-	-
Non Current Liabilities	30,049	21,850	40,362	34,996
<i>Long Term Borrowings</i>	24,688	17,169	36,913	31,054
<i>Deferred Tax Liabilities</i>	2,922	2,371	2,380	2,601
<i>Other Long Term Liabilities</i>	59	115	398	607
<i>Long Term Provisions</i>	2,380	2,195	670	734
Current Liabilities	27,784	38,944	21,425	26,158
<i>Short Term Borrowings</i>	11,314	11,878	5,172	4,310
<i>Trade Payables</i>	6,471	7,181	6,992	6,966
<i>Other Current Liabilities</i>	8,980	17,312	8,287	14,136
<i>Short-Term Provisions</i>	1,018	2,572	975	746
TOTAL EQUITY & LIABILITIES	83,709	88,638	86,322	88,245

INR m	Mar-13	Mar-14	Mar-15	Sep-15
ASSETS				
Non Current Assets	58,098	59,358	59,043	60,266
<i>Fixed Assets</i>	37,278	37,932	37,755	38,408
<i>Goodwill</i>	16,766	17,780	17,325	17,839
<i>Non Current Investments</i>	256	340	395	412
<i>Long-term loans and advances</i>	3,790	3,300	3,563	3,600
<i>Other Non-Current Assets</i>	9	6	6	5
Current Assets	25,611	29,280	27,279	27,980
<i>Inventories</i>	11,162	13,414	12,353	12,856
<i>Trade Receivables</i>	7,085	8,059	8,164	8,628
<i>Cash and Bank Balances</i>	3,561	4,795	3,943	3,735
<i>Short-Term Loans and Advances</i>	2,565	2,145	2,143	2,394
<i>Other Current Assets</i>	1,238	868	675	366
TOTAL ASSETS	83,709	88,638	86,322	88,245

Debt Profile

Particulars	Mar-15	Sep-15	Dec-15
Foreign Currency Loans	(\$m)	(\$m)	(\$m)
Standalone	105	80	65
Subsidiaries	338	338	347
Total	443	417	412
Rupee Loans	(INRm)	(INRm)	(INRm)
Standalone	15,133	14,211	12,630
Subsidiaries	5,091	5,523	5,422
Total	20,224	19,734	18,052
Gross Debt	47,904	47,099	45,295
Cash & Equivalent	3,943	3,735	2,053
Net Debt	43,961	43,364	43,242
Change in debt on account of exchange rate difference from 31-March, 2015		(1,289)	(1,507)
Net Debt - Adjusted for foreign exchange difference	43,961	42,075	41,735
Working Capital Debt	12,307	10,849	10,849
Net Long Term debt	31,654	32,515	32,393
Closing Exchange Rate (INR/USD)	62.5	65.59	66.16

- ▶ **Net debt** at INR 41,735 million on 31st Dec 2015 compared to INR 43,961 million on 31st Mar 2015 on constant currency basis
 - Net debt reduction of INR 2,226 million in 9M FY16
- ▶ **Blended interest rate** for the borrowings at 7.6% p.a. – Re loans @ 11.3% p.a., \$ loans @ 4.9% p.a.